<DOC>
	<DOCNO>NCT00135083</DOCNO>
	<brief_summary>The purpose study show non-inferiority insulin glulisine administer 1 meal versus 2 meal versus 3 daily meal , measure change hemoglobin A1c ( HbA1c ) , baseline study week 24 .</brief_summary>
	<brief_title>Variable Bolus Regimen 1-2-3 Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Subjects type 2 diabetes mellitus use stable combination oral antidiabetic therapy 2 3 agent different therapeutic class least 3 month enrol study . Male female subject 18 79 year age diagnosis type 2 diabetes mellitus least 6 month Current treatment stable dose 2 oral antidiabetic agent . The oral agent must 2 3 follow 3 different class : Sulfonylurea : dosage great equal , onehalf maximum recommend dosage ( eg , glimepiride &gt; /= 4 mg ; glipizide , include gastrointestinal therapeutic system [ GITS ] , &gt; /= 10 mg ; glyburide &gt; /= 10 mg ; Glynase® &gt; /=3 mg ) . The dosage must stable least 3 month prior screen . Biguanide : metformin dosage ≥ 1000 mg daily , include Glucophage XR® . The dosage must stable least 3 month prior screen . Thiazolidinedione ( TZD ) : pioglitazone &gt; /= 15 mg rosiglitazone &gt; /= 24 mg . The subject must use thiazolidinedione least 6 month , dosage must stable least 3 month prior screen . HbA1c &gt; /= 8.0 % Fasting Cpeptide concentration &gt; 0.27 nmol/L Able willing perform selfmonitoring blood glucose ( SMBG ) 4 time day Able willing adhere , compliant , study protocol Able read English Spanish sixthgrade level order complete subject report outcomes component study Signed informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization Insulin use within previous year History hypoglycemia unawareness Acute chronic , history , metabolic acidosis , include diabetic ketoacidosis Impaired renal function show , limited , serum creatinine ≥ 3mg/dL . For subject take metformin , serum creatinine &gt; /= 1.5 mg/dL male , &gt; /= 1.4 mg/dL female . Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level great 2.5 time upper limit normal ( ULN ) Clinically significant peripheral edema subject use TZD History stroke , myocardial infarction , coronary artery bypass graft , percutaneous transluminal coronary angioplasty , angina pectoris , within past 12 month History , current , congestive heart failure ( New York Heart Association [ NYHA ] IIIIV ) require pharmacologic treatment Acute infection Any malignancy within past 5 year , exception adequately treat basal squamous cell carcinoma adequately treat cervical carcinoma situ Current substance addiction alcohol abuse history substance alcohol abuse , within past 2 year Any clinically significant renal disease ( proteinuria ) hepatic disease Pregnant lactating female Dementia mental condition render subject unable understand nature , scope , possible consequence study Impaired dexterity vision render subject unable administer injection Known hypersensitivity insulin glargine insulin glulisine component Lantus Apidra Any disease condition ( include abuse illicit drug , prescription medication , alcohol ) , opinion investigator sponsor , may interfere completion study Unlikely comply protocol , eg , uncooperative attitude , inability return followup visit , unlikely complete study Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff , relative thereof , directly involve conduct protocol No subject allow enroll study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>